PriceTargets.com logo

Affimed - AFMD Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $16.00
  • Forecasted Upside: 359.77%
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$3.48 As of 11/15/2024 01:00 AM ET
▼ -0.17 (-4.66%)

This chart shows the closing price for AFMD by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Affimed Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for AFMD and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for AFMD

Analyst Price Target is $16.00
▲ +359.77% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Affimed in the last 3 months. The average price target is $16.00, with a high forecast of $25.00 and a low forecast of $4.00. The average price target represents a 359.77% upside from the last price of $3.48.

This chart shows the closing price for AFMD for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 5 polled investment analysts is to moderate buy stock in Affimed. This rating changed within the last month from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
5/27/2023
  • 0 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
8/25/2023
  • 0 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
11/23/2023
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
2/21/2024
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/21/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/19/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/18/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
11/17/2024

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
11/15/2024Stifel NicolausLower TargetHold ➝ Hold$5.00 ➝ $4.00
11/15/2024HC WainwrightReiterated RatingBuy ➝ Buy$10.00 ➝ $10.00
9/9/2024Cantor FitzgeraldReiterated RatingOverweight
9/6/2024HC WainwrightReiterated RatingBuy ➝ Buy$10.00 ➝ $10.00
6/13/2024LaidlawBoost TargetBuy$15.00 ➝ $25.00
6/13/2024HC WainwrightReiterated RatingBuy ➝ Buy$10.00 ➝ $10.00
6/3/2024HC WainwrightReiterated RatingBuy ➝ Buy$10.00 ➝ $10.00
4/1/2024Cantor FitzgeraldReiterated RatingOverweight
4/1/2024Wells Fargo & CompanyLower TargetOverweight ➝ Overweight$30.00 ➝ $25.00
4/1/2024HC WainwrightBoost TargetBuy ➝ Buy$10.00
11/15/2023HC WainwrightReiterated RatingBuy ➝ Buy$50.00
9/25/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$70.00
9/7/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$70.00
8/11/2023HC WainwrightReiterated RatingBuy ➝ Buy$50.00
8/11/2023Truist FinancialLower TargetBuy ➝ Buy$80.00 ➝ $60.00
8/8/2023Berenberg BankReiterated RatingBuy$60.00
6/5/2023HC WainwrightLower Target$60.00 ➝ $50.00
3/27/2023Wells Fargo & CompanyReiterated RatingOverweight$70.00
3/24/2023HC WainwrightReiterated RatingBuy$60.00
3/24/2023Stifel NicolausLower TargetHold$20.00 ➝ $10.00
12/12/2022Truist FinancialLower Target$120.00 ➝ $80.00
12/12/2022Wells Fargo & CompanyLower TargetOverweight$80.00 ➝ $70.00
12/12/2022Leerink PartnersLower TargetOutperform$100.00 ➝ $60.00
12/12/2022Piper SandlerLower TargetOverweight ➝ Overweight$70.00 ➝ $60.00
12/12/2022HC WainwrightInitiated CoverageBuy$60.00
10/10/2022Stifel NicolausDowngradeBuy ➝ Hold$90.00 ➝ $20.00
9/21/2022Cantor FitzgeraldReiterated RatingOverweight
8/18/2022Wells Fargo & CompanyReiterated RatingOverweight
6/23/2022Leerink PartnersLower TargetOutperform$100.00 ➝ $90.00
3/30/2022Piper SandlerInitiated CoverageOverweight$70.00
2/23/2022Cantor FitzgeraldInitiated CoverageOverweight$120.00
12/12/2021Leerink PartnersReiterated RatingBuy
11/17/2021Berenberg BankInitiated CoverageBuy
11/14/2021Leerink PartnersReiterated RatingBuy$120.00
10/21/2021Truist FinancialInitiated CoverageBuy$100.00
10/12/2021Leerink PartnersLower TargetOutperform$130.00 ➝ $120.00
9/29/2021Stifel NicolausInitiated CoverageBuy$120.00
4/18/2021Leerink PartnersReiterated RatingBuy
4/12/2021BMO Capital MarketsBoost TargetPositive ➝ Outperform$120.00 ➝ $150.00
3/30/2021Credit Suisse GroupInitiated CoverageOutperform$150.00
3/24/2021Wells Fargo & CompanyBoost TargetOverweight ➝ Overweight$100.00 ➝ $150.00
3/11/2021Leerink PartnersBoost TargetOutperform$90.00 ➝ $140.00
11/11/2020Leerink PartnersBoost TargetOutperform$80.00 ➝ $90.00
8/9/2020LaidlawReiterated RatingMarket Perform ➝ Buy$100.00
6/24/2020Leerink PartnersBoost TargetOutperform$70.00 ➝ $80.00
4/9/2020Leerink PartnersReiterated RatingOutperform
(Data available from 11/17/2019 forward)

News Sentiment Rating

0.29 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 6 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
4/21/2024
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/21/2024
  • 4 very positive mentions
  • 11 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
6/20/2024
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/20/2024
  • 5 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/19/2024
  • 2 very positive mentions
  • 10 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
9/18/2024
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/18/2024
  • 4 very positive mentions
  • 8 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
Mentions as of
11/17/2024

Current Sentiment

  • 4 very positive mentions
  • 8 positive mentions
  • 2 negative mentions
  • 1 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Affimed logo
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company's lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development for the treatment acute myeloid. It develops AFM32, an ICE candidate that is in preclinical development for the treatment of solid tumors. It has collaboration with Artiva Biotherapeutics to develop the combination of acimtamig and AlloNK; license and strategic collaboration agreement with Roivant Sciences Ltd. to develop and commercialize novel ICE molecules, including AFM32, in oncology; and strategic collaboration agreement with Genentech for the development of certain product candidates, which includes novel NK cell engager-based immunotherapeutics to treat multiple cancers. The company was formerly known as Affimed Therapeutics B.V. and changed its name to Affimed N.V. in October 2014. Affimed N.V. was founded in 2000 and is headquartered in Mannheim, Germany.
Read More

Today's Range

Now: $3.48
Low: $3.47
High: $3.76

50 Day Range

MA: $3.49
Low: $2.99
High: $4.07

52 Week Range

Now: $3.48
Low: $2.92
High: $8.95

Volume

132,609 shs

Average Volume

99,963 shs

Market Capitalization

$53.00 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.1

Frequently Asked Questions

What sell-side analysts currently cover shares of Affimed?

The following sell-side analysts have issued stock ratings on Affimed in the last twelve months: Cantor Fitzgerald, HC Wainwright, Laidlaw, Stifel Nicolaus, StockNews.com, and Wells Fargo & Company.
View the latest analyst ratings for AFMD.

What is the current price target for Affimed?

0 Wall Street analysts have set twelve-month price targets for Affimed in the last year. Their average twelve-month price target is $16.00, suggesting a possible upside of 359.8%. Wells Fargo & Company has the highest price target set, predicting AFMD will reach $25.00 in the next twelve months. Stifel Nicolaus has the lowest price target set, forecasting a price of $4.00 for Affimed in the next year.
View the latest price targets for AFMD.

What is the current consensus analyst rating for Affimed?

Affimed currently has 1 hold rating and 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for AFMD.

What other companies compete with Affimed?

Other companies that are similar to Affimed include Trevi Therapeutics, Amarin, XBiotech, Corbus Pharmaceuticals and 2seventy bio. Learn More about companies similar to Affimed.

How do I contact Affimed's investor relations team?

Affimed's physical mailing address is TECHNOLOGIEPARK IM NEUENHEIMER FELD 582, HEIDELBERG 2M, 69120. The biopharmaceutical company's listed phone number is 496221674360 and its investor relations email address is [email protected]. The official website for Affimed is www.affimed.com. Learn More about contacing Affimed investor relations.